Nal.pone.0052096.gInfusion Tol-DC Prolongs Islet Allograft SurvivalFigure 3. Effects of allopeptide-pulsed

Nal.pone.0052096.gInfusion Tol-DC Prolongs Islet Allograft SurvivalFigure 3. Effects of allopeptide-pulsed host Epigenetic Reader Domain Tol-DCs on islet graft survival. A) Single-injection of alloAg-imDC. B) AlloAg-imDC plus ALS group. imDC-alloAg: Allopeptide-pulsed imDC. doi:10.1371/journal.pone.0052096.gsuggests that additional injections did not contribute more to promoting survival, but instead increased the risk and cost. Other derived Tol-DC prolonged Epigenetic Reader Domain grafts survival. Three studies used Tol-DCs derived from donor spleen or 1676428 liver. Compared to controls, Tol-DCs prolonged graft survival (2.666.89 d), while only liver-derived DCs favored islet allograft survival, and donor spleen-derived DCs showed rejection episodes in two studies (Figure 7 A). Kim et al. demonstrated pre-treatment of hosts with either CD4+DCs or CD8+DCs did not produce prolonged islet allograft survival compared with controls, but did prolong survival when combined with antiCD154Ab [16] (Figure 7 B). Furthermore, the provision of anti-CD154Ab plus CD4+DCs created tolerance, but not CD8+DCs (Figure 7 B). This suggeststhat DC subsets and co-stimulatory signals play an important role on graft survival. Beyond that, Chaib et al. reported animals receiving intrathymic inoculation with liver non-parenchymal cells (NPC) or spleen DCs plus ALS, rejected islet allografts. This is in contrast to their previously published 25837696 work where tolerance to cardiac grafts was induced by intrathymic NPC inoculation under transient immunosuppression with ALS, prompting them to speculate that organ-specific tolerance was induced by NPC through their experimental protocol [17]. Summary of main results. According to GRADE standards, we made a summary table of the key results to summarize the data and effect sizes of important endpoint outcomes (Table 3). Although gene modification of DCs was the most commonly used-Figure 4. Effects of drug intervention Tol-DCs on islet allograft survival. A) mDC+VAF347. B) imDC or mDC with/without VAF347. VAF347: VAF347 is a low-molecular-weight compound, which can modify immune responses through induction of Tol-DC, and activating AhR resulted in induction of Foxp3+Treg cells. doi:10.1371/journal.pone.0052096.gInfusion Tol-DC Prolongs Islet Allograft SurvivalFigure 5. Effects of MSC-induced Tol-DCs on islet allograft survival. A) Recipient-KSC+Donor-DC. B) Recipient-KSC+Recipient/Donor-DC. doi:10.1371/journal.pone.0052096.gmethod in MHC mismatched islet allografts, allopeptide-pulsed Tol-DCs were most effective at prolonging survival. The main route of administration in this model was intravenous, but intrathymic injection showed the best results. Single-injection dose of 1?6105 DCs was most commonly used, yet the104 group clearly prolonged survival compared with other doses. Multiple injections did not make substantive contributions to promoting survival, but instead increased the risks and costs. Due to the limited number of studies included and incomplete data, more high quality studies with larger sample sizes are still needed.Possible mechanisms underlying Tol-DCs prolonging graft survival. Infusion of Tol-DCs likely prolonged isletDiscussion Tol-DCs significantly prolong islet allograft survival through various mechanismsInduction of maturation-resistant and stable tolerogenic DCs is a prerequisite for its application in the clinic. Our systematic review identified five kinds of Tol-DCs that had different effects on islet graft survival (Table 3). The route of injection also.Nal.pone.0052096.gInfusion Tol-DC Prolongs Islet Allograft SurvivalFigure 3. Effects of allopeptide-pulsed host Tol-DCs on islet graft survival. A) Single-injection of alloAg-imDC. B) AlloAg-imDC plus ALS group. imDC-alloAg: Allopeptide-pulsed imDC. doi:10.1371/journal.pone.0052096.gsuggests that additional injections did not contribute more to promoting survival, but instead increased the risk and cost. Other derived Tol-DC prolonged grafts survival. Three studies used Tol-DCs derived from donor spleen or 1676428 liver. Compared to controls, Tol-DCs prolonged graft survival (2.666.89 d), while only liver-derived DCs favored islet allograft survival, and donor spleen-derived DCs showed rejection episodes in two studies (Figure 7 A). Kim et al. demonstrated pre-treatment of hosts with either CD4+DCs or CD8+DCs did not produce prolonged islet allograft survival compared with controls, but did prolong survival when combined with antiCD154Ab [16] (Figure 7 B). Furthermore, the provision of anti-CD154Ab plus CD4+DCs created tolerance, but not CD8+DCs (Figure 7 B). This suggeststhat DC subsets and co-stimulatory signals play an important role on graft survival. Beyond that, Chaib et al. reported animals receiving intrathymic inoculation with liver non-parenchymal cells (NPC) or spleen DCs plus ALS, rejected islet allografts. This is in contrast to their previously published 25837696 work where tolerance to cardiac grafts was induced by intrathymic NPC inoculation under transient immunosuppression with ALS, prompting them to speculate that organ-specific tolerance was induced by NPC through their experimental protocol [17]. Summary of main results. According to GRADE standards, we made a summary table of the key results to summarize the data and effect sizes of important endpoint outcomes (Table 3). Although gene modification of DCs was the most commonly used-Figure 4. Effects of drug intervention Tol-DCs on islet allograft survival. A) mDC+VAF347. B) imDC or mDC with/without VAF347. VAF347: VAF347 is a low-molecular-weight compound, which can modify immune responses through induction of Tol-DC, and activating AhR resulted in induction of Foxp3+Treg cells. doi:10.1371/journal.pone.0052096.gInfusion Tol-DC Prolongs Islet Allograft SurvivalFigure 5. Effects of MSC-induced Tol-DCs on islet allograft survival. A) Recipient-KSC+Donor-DC. B) Recipient-KSC+Recipient/Donor-DC. doi:10.1371/journal.pone.0052096.gmethod in MHC mismatched islet allografts, allopeptide-pulsed Tol-DCs were most effective at prolonging survival. The main route of administration in this model was intravenous, but intrathymic injection showed the best results. Single-injection dose of 1?6105 DCs was most commonly used, yet the104 group clearly prolonged survival compared with other doses. Multiple injections did not make substantive contributions to promoting survival, but instead increased the risks and costs. Due to the limited number of studies included and incomplete data, more high quality studies with larger sample sizes are still needed.Possible mechanisms underlying Tol-DCs prolonging graft survival. Infusion of Tol-DCs likely prolonged isletDiscussion Tol-DCs significantly prolong islet allograft survival through various mechanismsInduction of maturation-resistant and stable tolerogenic DCs is a prerequisite for its application in the clinic. Our systematic review identified five kinds of Tol-DCs that had different effects on islet graft survival (Table 3). The route of injection also.